Genentech Inc. has turned to Sosei Heptares to help it to discover and develop medicines that are capable of modulating G protein-coupled receptors (GPCRs), a very large and diverse gene family with a lot of promising drug targets within it. Under the terms of the deal, the collaboration will combine Sosei Heptares’ GPCR-focused structure-based drug design capabilities with Genentech’s discovery, development and therapeutic are expertise directed towards multiple Genentech-nomimated GPCR targets. Genentech will be responsible for developing and commercializing potential new medicines for each novel target and will have exclusive global rights to them.
“In the partnership, we expect to apply our StaR platform to targets they have selected and take the initial DNA,...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?